Ultragenyx’s Rare Bootcamp gives families a roadmap to help drive research and develop new treatments for rare diseases.

Organoids are miniature tissue or organ models formed by stem cells (including pluripotent stem cells, tissue-specific adult ...

Membrane proteins present significant technical challenges in drug discovery, yet their role in biology make them highly ...

Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx’s Rare ...

The evolving role of early-phase clinical trials reflects a broader truth: decisions made early carry increasing weight in ...

The UK-led OpenBind initiative has reached a major milestone with the release of its first publicly available dataset and ...

Traws Pharma, Inc. TRAW shares are up during Friday’s session, trading higher by 25.86% as the company is advancing potential clinical candidates for the treatment of hantavirus infections. Traws ...

The FDA rejected the promising skin cancer drug RP1 twice, leaving many puzzled and worried about what this means for other ...

Synthetic” and “natural” are largely useless terms. But not “semisynthetic.” It’s a real word that describes a critical ...

The model is already live with early pharma partners Amgen and AstraZeneca. An AstraZeneca-sponsored Phase 2 trial is ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

Antibody-drug conjugates (ADCs) have emerged as the primary solution for patients who have progressed on EGFR inhibitors and ...